Related Experiment Videos
Sacral neuromodulation for the management of severe constipation: development of a constipation treatment protocol
Abhiram Sharma1, Ben Liu, Philip Waudby
1Academic Surgical Unit, University of Hull, Castle Hill Hospital, Cottingham, Hull, HU16 5JQ, UK. abhisurgery@gmail.com
Background:
Constipation is a common multifactorial gastrointestinal symptom with quality of life implications. Sacral neuromodulation has been used in the management of severe constipation with mixed results. The aim of this study was to review our experience of sacral neuromodulation as a treatment for chronic constipation and develop a chronic constipation management protocol.
Methods:
In patients with severe constipation, failure of conservative management including biofeedback and rectal irrigation were considered for neuromodulation. Temporary stimulation lead was placed in the sacral foramen of eligible patients and pre and post stimulation bowel diaries were compared. Patients with ≥50% improvement in bowel diaries had permanent implant. Patients were followed up at 2 and 4 weeks, 3, 6, and 12 months, and then yearly with bowel diaries.
Results:
Temporary neuromodulation wires were implanted in 21 patients (20 female). Significant bowel diary improvement was seen in 12 (57%) patients (p < 0.01). Eleven permanent implants have been performed. Improvement in symptoms was lost in one patient. No major side effects were observed. Three patients have had reoperations (one wire fracture, one reposition of battery, and one poor initial lead placement). Improvements in bowel diaries have been maintained over a median follow-up period of 38 months (18-62 months).
Conclusion:
Sacral neuromodulation can provide long-term symptom relief in selected patients with severe constipation. Sacral neuromodulation should be incorporated into the treatment algorithm for chronic constipation.
Related Concept Videos
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Irritable Bowel Syndrome III: Medical and Nursing Management
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...
Drugs Affecting GI Tract Motility: Other Laxatives
Osmotic or saline laxatives, like magnesium hydroxide or milk of...